Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that 14 company-sponsored COPAXONE® and laquinimod abstracts, including three oral presentations, were highlighted at the 66th annual American Academy of Neurology (AAN) meeting in Philadelphia, Pa. New data presented adds to the understanding of the clinical utility of three-times-a-week COPAXONE® 40 mg/mL and provides additional findings on its efficacy, safety, and tolerability profile.
Help employers find you! Check out all the jobs and post your resume.
